Lymphomas show a higher incidence and poorer prognosis in males than in females, which suggests a role for endocrine regulation in this cancer. Yakimchuk et al. used xenograft mouse models of human lymphomas to show that ligand-mediated oestrogen receptor-β (ERβ) activation inhibits angiogenesis and lymphangiogenesis. These effects are not thought to be mediated by the microenvironment, as there was no difference between wild-type and ERβ-deficient mice engrafted with lymphoma cells. Furthermore, they showed that human lymphoma biopsies express ERβ, which suggests that ERβ agonists could be a viable therapy for lymphoma.